Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
Riociguat is a soluble, guanylate cyclase stimulator, approved for pulmonary arterial hypertension. In the 12-week PATENT-1 study, riociguat was well tolerated and improved several clinically relevant end-points in patients with pulmonary arterial hypertension who were treatment naïve or had been p...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 January 2015
|
| In: |
The European respiratory journal
Year: 2015, Volume: 45, Issue: 5, Pages: 1303-1313 |
| ISSN: | 1399-3003 |
| DOI: | 10.1183/09031936.00090614 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1183/09031936.00090614 Verlag, kostenfrei, Volltext: http://erj.ersjournals.com/content/45/5/1303 
|
| Author Notes: | Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie, Hossein-Ardeschir Ghofrani |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1558774947 | ||
| 003 | DE-627 | ||
| 005 | 20220813174148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170518s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/09031936.00090614 |2 doi | |
| 035 | |a (DE-627)1558774947 | ||
| 035 | |a (DE-576)488774942 | ||
| 035 | |a (DE-599)BSZ488774942 | ||
| 035 | |a (OCoLC)1340975607 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rubin, Lewis J. |e VerfasserIn |0 (DE-588)141257954 |0 (DE-627)703927345 |0 (DE-576)32302484X |4 aut | |
| 245 | 1 | 0 | |a Riociguat for the treatment of pulmonary arterial hypertension |b a long-term extension study (PATENT-2) |c Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie, Hossein-Ardeschir Ghofrani |
| 264 | 1 | |c 22 January 2015 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.05.2017 | ||
| 520 | |a Riociguat is a soluble, guanylate cyclase stimulator, approved for pulmonary arterial hypertension. In the 12-week PATENT-1 study, riociguat was well tolerated and improved several clinically relevant end-points in patients with pulmonary arterial hypertension who were treatment naïve or had been pretreated with endothelin-receptor antagonists or prostanoids. The PATENT-2 open-label extension evaluated the long-term safety and efficacy of riociguat. Eligible patients from the PATENT-1 study received riociguat individually adjusted up to a maximum dose of 2.5 mg three times daily. The primary objective was to assess the safety and tolerability of riociguat; exploratory efficacy assessments included 6-min walking distance and World Health Organization (WHO) functional class. Overall, 396 patients entered the PATENT-2 study and 324 (82%) were ongoing at this interim analysis (March 2013). The safety profile of riociguat in PATENT-2 was similar to that observed in PATENT-1, with cases of haemoptysis and pulmonary haemorrhage also being observed in PATENT-2. Improvements in the patients', 6-min walking distance and WHO functional class observed in PATENT-1 persisted for up to 1 year in PATENT-2. In the observed population at the 1-year time point, mean±sd 6-min walking distance had changed by 51±74 m and WHO functional class had improved in 33%, stabilised in 61% and worsened in 6% of the patients versus the PATENT-1 baseline. Long-term riociguat was well tolerated in patients with pulmonary arterial hypertension, and led to sustained improvements in exercise capacity and functional capacity for up to 1 year. Riociguat was well tolerated in patients with PAH, with sustained benefits in 6MWD and WHO FC for up to 1 year http://ow.ly/EskBj | ||
| 700 | 1 | |a Grünig, Ekkehard |e VerfasserIn |0 (DE-588)112535801 |0 (DE-627)618892605 |0 (DE-576)31856694X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European respiratory journal |d Lausanne : ERS, 1988 |g 45(2015), 5, Seite 1303-1313 |h Online-Ressource |w (DE-627)306646803 |w (DE-600)1499101-9 |w (DE-576)091142504 |x 1399-3003 |7 nnas |a Riociguat for the treatment of pulmonary arterial hypertension a long-term extension study (PATENT-2) |
| 773 | 1 | 8 | |g volume:45 |g year:2015 |g number:5 |g pages:1303-1313 |g extent:11 |a Riociguat for the treatment of pulmonary arterial hypertension a long-term extension study (PATENT-2) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/09031936.00090614 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://erj.ersjournals.com/content/45/5/1303 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170518 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 112535801 |a Grünig, Ekkehard |m 112535801:Grünig, Ekkehard |d 910000 |d 950000 |d 950900 |e 910000PG112535801 |e 950000PG112535801 |e 950900PG112535801 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 4 | ||
| 999 | |a KXP-PPN1558774947 |e 2969688166 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"corporate":[{"role":"isb","display":"European Respiratory Society"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"zdb":["1499101-9"],"issn":["1399-3003"],"eki":["306646803"]},"language":["eng"],"origin":[{"publisher":"ERS ; Munksgaard","dateIssuedKey":"1988","dateIssuedDisp":"1988-","publisherPlace":"Lausanne ; Copenhagen"}],"part":{"volume":"45","text":"45(2015), 5, Seite 1303-1313","pages":"1303-1313","extent":"11","year":"2015","issue":"5"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"flagship scientific journal of ERS","title":"The European respiratory journal","title_sort":"European respiratory journal"}],"titleAlt":[{"title":"official journal of the European Society for Clinical Respiratory Physiology : ERJ"},{"title":"ERJ"}],"disp":"Riociguat for the treatment of pulmonary arterial hypertension a long-term extension study (PATENT-2)The European respiratory journal","pubHistory":["1.1988 -"],"note":["Gesehen am 25.04.2025","Fortsetzung der Druck-Ausgabe"],"recId":"306646803","name":{"displayForm":["European Respiratory Society"]}}],"title":[{"title_sort":"Riociguat for the treatment of pulmonary arterial hypertension","title":"Riociguat for the treatment of pulmonary arterial hypertension","subtitle":"a long-term extension study (PATENT-2)"}],"person":[{"role":"aut","given":"Lewis J.","family":"Rubin","display":"Rubin, Lewis J."},{"family":"Grünig","display":"Grünig, Ekkehard","given":"Ekkehard","role":"aut"}],"physDesc":[{"extent":"11 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1558774947"],"doi":["10.1183/09031936.00090614"]},"language":["eng"],"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"22 January 2015"}],"recId":"1558774947","note":["Gesehen am 18.05.2017"],"name":{"displayForm":["Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie, Hossein-Ardeschir Ghofrani"]}} | ||
| SRT | |a RUBINLEWISRIOCIGUATF2220 | ||